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Abstract
Background: Better treatment during early stages of chronic kidney disease (CKD) may slow progression to end-
stage renal disease and decrease associated complications and medical costs. Achieving early treatment of CKD is
challenging, however, because a large fraction of persons with CKD are unaware of having this disease. Screening
for CKD is one important method for increasing awareness. We examined the cost-effectiveness of identifying
persons for early-stage CKD screening (i.e., screening for moderate albuminuria) using published CKD risk scores.
Methods: We used the CKD Health Policy Model, a micro-simulation model, to simulate the cost-effectiveness of
using CKD two published risk scores by Bang et al. and Kshirsagar et al. to identify persons in the US for CKD
screening with testing for albuminuria. Alternative risk score thresholds were tested (0.20, 0.15, 0.10, 0.05, and 0.02)
above which persons were assigned to receive screening at alternative intervals (1-, 2-, and 5-year) for follow-up
screening if the first screening was negative. We examined incremental cost-effectiveness ratios (ICERs), incremental
lifetime costs divided by incremental lifetime QALYs, relative to the next higher screening threshold to assess cost-
effectiveness. Cost-effective scenarios were determined as those with ICERs less than $50,000 per QALY. Among the
cost-effective scenarios, the optimal scenario was determined as the one that resulted in the highest lifetime QALYs.
Results: ICERs ranged from $8,823 per QALY to $124,626 per QALY for the Bang et al. risk score and $6,342 per QALY
to $405,861 per QALY for the Kshirsagar et al. risk score. The Bang et al. risk score with a threshold of 0.02 and 2-year
follow-up screening was found to be optimal because it had an ICER less than $50,000 per QALY and resulted in the
highest lifetime QALYs.
Conclusions: This study indicates that using these CKD risk scores may allow clinicians to cost-effectively identify a
broader population for CKD screening with testing for albuminuria and potentially detect people with CKD at earlier
stages of the disease than current approaches of screening only persons with diabetes or hypertension.
Keywords: Chronic kidney disease, Risk scores, Screening
Background
Chronic kidney disease (CKD) affected 13.6% of U.S.
adults in 2007–2012 [1] and is estimated to affect nearly
17% of adults by 2030 [2]. All stages of CKD have been
shown to impose significant health and economic burden
[3–5]. Better treatment during early stages of CKD may
slow progression to end-stage renal disease (ESRD), the
most severe stage of CKD, and reduce complications,
medical costs, and mortality associated with CKD [6–9].
Achieving early treatment of CKD is challenging, however,
because as many as 94.5% of persons with CKD are un-
aware of having the disease [10, 11]. Therefore, increasing
awareness among patients and clinicians about CKD and
CKD screening is important to achieve earlier treatment
of CKD and mitigate its associated costs and complica-
tions. Screening for moderately increased albuminuria
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(microalbuminuria), a marker of early-stage CKD, was
found to be cost-effective in populations with diabetes or
hypertension [12–14]. Diabetes and hypertension are pri-
mary risk factors for CKD, but approximately 52% of those
with CKD do not have diabetes, and approximately 10%
do not have hypertension [1]. Thus, identifying cost-
effective methods of screening for CKD in other popula-
tions is crucial to increase awareness of CKD and CKD
screening among patients and clinicians and to improve
early detection and management of CKD.
Using CKD risk scores to identify persons for CKD
screening with testing for albuminuria may prove to be a
cost-effective method for identifying a population broader
than just those with diabetes or hypertension. In this
study, we used the CKD Health Policy Model, a microsi-
mulation model of CKD progression, to examine the cost-
effectiveness of identifying persons for early-stage CKD
screening (i.e., screening for moderate albuminuria) using
two published CKD risk scores: one published by Bang et
al. [15] and one published by Kshirsagar et al. [16]. We
assessed the cost-effectiveness of alternative screening sce-
narios by varying risk score thresholds above which per-
sons were assigned to receive screening and frequencies of
follow-up screening if the initial test was negative.
Methods
Model overview
This study used the CKD Health Policy Model in 2015, a
microsimulation model of CKD progression [2, 12, 17, 18].
Briefly, the model simulates progression of CKD and its
complications in a nationally representative cohort drawn
from the National Health and Nutrition Examination Sur-
vey (NHANES) through age 90 years or death. The model
includes eight states: no CKD, CKD stages 1 through 5
(with stage 3 divided into 3a and 3b), and death. CKD
stages are defined by estimated glomerular filtration rates
(eGFR) and the presence of elevated albuminuria (urinary
albumin to creatinine ratio ≥30 mg/g) [19]. The model
concomitantly simulates the natural history of complica-
tions from CKD. Model parameters are derived from the
epidemiological literature, clinical trials, and a previous
cost-effectiveness study [14].
Importantly, the model simulates screening for mod-
erate and severe albuminuria. Figure 1 presents the
screening and treatment pathway in the model for a
person diagnosed with CKD. In the model, treatment
with angiotensin-converting enzyme (ACE) inhibitors
or angiotensin receptor blockers (ARBs) decreases the
probability of progression from moderate to severe
Fig. 1 Flowchart of CKD screening and treatment in the CKD health policy model. ACE, angiotensin-converting enzyme inhibitor; ACR, albumin-
to-creatinine ratio; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; GFR, glomerular filtration rate
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albuminuria, slows the annual decline in GFR for
persons with moderate albuminuria, and reduces the
annual mortality rate for persons with moderate albu-
minuria. The model does not include parameters re-
lated to possible harms associated with screening,
incidental findings, or over-diagnosis, but because of
the two stage test and the sensitivity and specificity pa-
rameters, we expect misdiagnosis to be low. Model pa-
rameters related to CKD screening and treatments with
ACE inhibitors or ARBs are shown in Table 1.
Table 1 Model Parameters for Albuminuria Screening, Treatment with Renin-angiotensin System Inhibitors, and Screening and




Sensitivity of screening test for moderate albuminuria 0.73 Sarafidis et al. [23]
Specificity of screening test for moderate albuminuria 0.96 Sarafidis et al. [23]
Treatment adherence of persons diagnosed with moderate
albuminuria
0.75 Boulware et al. [14]
Treatment effect relative risks (multiplied by baseline rates)
Relative risk of moderate- to severe albuminuria transition for
persons receiving treatment
0.45 Strippoli et al. [6]
Relative risk of mortality for persons with moderate albuminuria
receiving treatment
0.77 Boulware et al. [14]
Relative risk of annual GFR decrease in persons with for persons
with moderate albuminuria receiving treatment
0.67 Agodoa et al. [7] Ruggenenti et al. [8, 9]
Annual QALY decrement from CKD and related complications
Proteinuria 0.01 Gorodetskaya et al. [24]
GFR 30–59 0.05 Gorodetskaya et al. [24]
GFR 15–29 0.07 Gorodetskaya et al. [24]
GFR <15 0.20 Gorodetskaya et al. [24]
Stroke, ever 0.582 Meenan et al. [25]
CA/MI, current year 0.12 Tsevat et al. [26]
CHD, ever without MI 0.053 Nease et al. [27]
Screening costs (2016 US $)
Initial visit 88.58 CMS [28]
Second visit if positive during first visit 69.08 CMS [28]
One time costs of diagnostic tests to assess for CKD if GFR <60 ml/min/1.73 m2 (2010 $)
Diabetes or hypertension 382.41 Boulware et al. [14, 20]; CMS [29]; AHRQ [30]
Neither hypertension nor diabetes: Severe albuminuria
and age < 65
2,857.10 Boulware et al. [14, 20]; CMS [29]; AHRQ [30]
Neither hypertension nor diabetes: Moderate albuminuria
and age <65
1,401.40 Boulware et al. [14, 20]; CMS [29]; AHRQ [30]
Neither hypertension nor diabetes: Age ≥65 964.69 Boulware et al. [14, 20]; CMS [29]; AHRQ [30]
Annual follow-up costs if GFR <60 ml/min/1.73 m2 (2016 US $)
Specialist visit:
Diabetes 94.15 Boulware et al. [14]; CMS [28]
No diabetes 85.23 Boulware et al. [14]; CMS [28]
General practitioner visit 132.88 Boulware et al. [14]; CMS [28]
Annual drug therapy
ARBs (diabetes) 527.49 Boulware et al. [14]; Rodby et al .[31]; Lewis et al. [32]; Nakao et al. [33];
Jafar et al. [34]; Drug Topics Red Book [35]; AHRQ [36]
ACE inhibitors (no diabetes) 210.03
Annual rate at which costs and QALYs are discounted
(i.e. reduced)
3% Weinstein et al. [21]
GFR glomerular filtration rate, ACE angiotensin converting enzyme inhibitor, AHRQ Agency for Healthcare Research and Quality, ARB angiotensin receptor blocker,
CKD chronic kidney disease, CMS Centers for Medicare & Medicaid Services
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Costs
Costs in the model are lifetime costs (i.e. from model
start to death) from the health care perspective. This in-
cludes all paid by insurers and paid out of pocket by pa-
tients (Table 1). The model does not include physician
time for training in the use of the risk score although we
expect that this may be minimal since the risk score can
be implemented in existing EHRs. The model includes
measures of costs for CKD screening. Initial costs in-
clude a physician visit to measure urine albumin and
creatinine levels to identify the presence of moderate al-
buminuria and, if the test is positive, a second physician
visit to confirm the presence of moderate albuminuria.
Once the presence of moderate albuminuria has been
confirmed, additional diagnostic costs are incurred if the
person has eGFR less than 60 ml/min per 1.73 m2. The
tests included in the one-time diagnosis costs are those
identified in Boulware et al. [14, 20] as being most fre-
quently recommended by primary care providers to test
for CKD. Persons with moderate albuminuria also have
annual treatment costs that include physician follow-up
and either ACE inhibitors if they do not have diabetes or
ARBs if they do. Costs are given in 2010 US dollars. To
incorporate time preferences (i.e. persons prefer dollars
and quality of life in the present to dollars and quality of
life in the future), costs are discounted (i.e. reduced) by
3% annually as recommended for all cost-effectiveness
analysis by Weinstein et al. [21].
Risk scores
We assigned persons to receive CKD screening based on
published risk scores. Risk scores were identified from
literature review based on four criteria: (1) the predictive
factors are commonly collected as part of regular phys-
ician office visits to ensure that the risk score can be feas-
ibly implemented to identify a broad population for CKD
screening, (2) the study pertains to the U.S. population,
(3) the study has good internal predictive ability, and (4)
the study has good external predictive ability as measured
using external data sources. We allowed for the inclusion
of some factors—diabetes, cholesterol, and anemia—that
are collected at office visits with slightly less regularity.
Two risk scores were identified based on these criteria:
one published by Bang et al. [15] and one published by
Kshirsagar et al. [16] Bang et al. used logistic regression
to predict current CKD (stage 3+) in the NHANES popu-
lation and validated the prediction model in the Athero-
sclerosis Risk in Communities (ARIC) study. Kshirsagar et
al. used logistic regression to predict onset of CKD (stage
3+) over the 9-year study period in subsamples of ARIC
and the Cardiovascular Health Study (CHS) and validated
the prediction model in other subsamples from ARIC and
CHS.
The Bang et al. and Kshirsagar et al. risk scores range
from zero to one and correspond to a person’s level of
risk for having or developing CKD. Because the Bang et
al. risk score is based on single observations per person
in NHANES, it can be interpreted as the probability of a
person having prevalent CKD. Because the Kshirsagar et
al. risk score is based on longitudinal data from ARIC
and CHS, it can be interpreted as the probability of de-
veloping CKD over 4 to 9 years of follow up. Clinically,
the Bang et al. and Kshirsagar et al. risk scores can be
used to evaluate a patient’s overall risk and determine
whether the patient should receive CKD screening. Table 2
shows examples of the Bang et al. and Kshirsagar et al. risk
scores for persons with different characteristics. The Bang
et al. risk scores are generally lower for each group, except
for those over age 70. The Bang et al. and Kshirsagar et al.
risk scores are used only to identify persons at high risk of
CKD who should receive screening. Coefficients from the
logistic regressions for the two risk scores are shown in
Table 3. These coefficients are derived from logistic re-
gressions, so logistic transformation was used to construct
risk scores in the model cohort, based on each person’s
risk factors. The two risk scores are constructed using
largely similar risk factors.
After determining a person’s risk score, it was neces-
sary to determine the risk score threshold over which a
person is assigned to receive early-stage CKD screening
(i.e., screening for moderate albuminuria). No optimal
threshold was defined ex-ante, so five alternative thresh-
olds (0.20, 0.15, 0.10, 0.05, and 0.02) were tested for the
Bang et al. and Kshirsagar et al. risk scores. This range
of thresholds was chosen because of the concentration
of risk scores at the lower range of the distribution. For
both risk scores, 95% of the cohort had a risk score less
than 0.20. Persons with risk scores less than or equal to
the threshold did not receive any screening or follow-up
until their risk scores rose above the threshold. Once a
person’s risk score rose above the risk score threshold,
he or she was assigned to receive screening for moderate
albuminuria. If the initial screening was negative, the
person received a follow-up screening for moderate al-
buminuria at a specified interval. Because no optimal
interval was defined ex-ante, we tested three intervals:
1 year, 2 years, and 5 years. These intervals were chosen
because they have been used in past measures of CKD
screening,[12] although there is no definitive recommen-
dation for follow-up interval.
Incremental cost-effectiveness ratios
Lifetime costs and quality-adjusted life years (QALYs)
were simulated for the screening scenarios using the Bang
et al. and Kshirsagar et al. risk scores described above for
a nationally representative cohort drawn aged 30 or
older from the 1999–2010 NHANES. The increment
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we evaluate is a change from the next highest risk score
threshold, so each incremental change represents an in-
crease in the number of people screened due to a lower
risk score threshold. Lifetime costs and lifetime QALYs
for each scenario were compared with the next higher
risk score threshold to evaluate incremental costs and
QALYs. The incremental cost-effectiveness ratios
(ICERs) were computed as incremental lifetime cost di-
vided by incremental lifetime QALYs for each screening
scenario. Costs and QALYs were discounted (i.e. reduced) at
a 3% annual rate, as recommended for all cost-effectiveness
analysis by Weinstein et al. [21] We computed 95% confi-
dence intervals for each ICER using a probabilistic sensitivity
analysis where we allowed the following key model
Table 2 Example Bang et al. and Kshirsagar et al. Risk Scores for Persons with Different Characteristics
Risk Score No Risk Factors Diabetes Diabetes and Hypertension Diabetes, Hypertension, and Anemia Cardiovascular Disease
Bang et al.
Female: Age < 50 0.01 0.01 0.01 0.04 0.06
Female: Age 50 to 59 0.03 0.04 0.06 0.15 0.24
Female: Age 60 to 69 0.06 0.09 0.13 0.27 0.40
Female: Age ≥ 70 0.13 0.19 0.27 0.49 0.63
Male: Age < 50 0.00 0.01 0.01 0.03 0.05
Male: Age 50 to 59 0.02 0.03 0.05 0.12 0.19
Male: Age 60 to 69 0.04 0.07 0.10 0.22 0.34
Male: Age≥ 70 0.10 0.15 0.22 0.41 0.56
Kshirsagar et al.
Female: Age < 50 0.04 0.06 0.09 0.14 0.18
Female: Age 50 to 59 0.07 0.10 0.16 0.24 0.28
Female: Age 60 to 69 0.14 0.18 0.28 0.38 0.45
Female: Age ≥ 70 0.15 0.20 0.30 0.41 0.48
Male: Age < 50 0.04 0.05 0.08 0.13 0.16
Male: Age 50 to 59 0.06 0.09 0.14 0.21 0.26
Male: Age 60 to 69 0.12 0.16 0.25 0.35 0.41
Male: Age≥ 70 0.14 0.18 0.28 0.38 0.45
The Bang et al. risk score is derived from a logistic regression to predict current CKD (stage 3+) in the NHANES population. The Kshirsagar et al. risk score is derived from
a logistic regression to predict onset of CKD (stage 3+) over the 9-year study period in subsamples of ARIC and the Cardiovascular Health Study (CHS). Coefficients used
to generate the risk scores are given in Table 3
Table 3 Logistic Regression Coefficients by Individual Characteristics from Bang et al. and Kshirsagar et al. Risk Scores
Individual Characteristic Bang et al. Risk Score Coefficient [15] Kshirsagar et al. Risk Score Coefficient [16]
Age (Reference: 18 to 49)
50 to 59 1.55 0.63







History of cardiovascular disease 0.59 0.26
History of congestive heart failure 0.45 0.50
Constant −5.40 −3.30
aSystolic blood pressure ≥ 140 mm/hg and/or diastolic blood pressure ≥ 90 mm/hg and/or use of antihypertensive medications
bHemoglobin (Hb) concentration <12.0 g/dl
cUrinary Protein Excretion ≥ 30 mg/dl
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parameters to vary according to distributions taken from the
literature: the hazard ratio of ACE inhibitor/ARB treatment
on transition from moderate to severe albuminuria, the haz-
ard ratio of ACE inhibitor/ARB treatment on eGFR decline,
the hazard ratio of ACE inhibitor/ARB treatment on the an-
nual mortality rate, ACE inhibitor inhibitor/ARB adherence,
the costs of screening, and the costs of ACE inhibitor/ARB
treatment.
Cost-effectiveness of any screening scenario depends
on the specific willingness to pay for additional QALYs.
The commonly used benchmark is $50,000 per QALY
[22]. A screening scenario was determined to be cost-
effective if the ICER per QALY gained is less than the
willingness to pay threshold. The optimal scenario was
determined as the cost-effective scenario that yields
highest QALYs gained.
Model validation
The external validity of the model was tested against data
from the longitudinal ARIC study. The ARIC study
tracked persons over approximately 9 years and included
4 office visits to collect laboratory data and health status
information. Data from the first ARIC office visit were
used to populate the simulation cohort in the model valid-
ation. We simulated 9 years in the model for this cohort
and generated the distribution of the change in eGFR. The
distribution of the actual change in eGFR between the first
and last office visit in the ARIC study was compared with
the simulated distribution to examine the performance of
the model.
Results from validation testing of eGFR progression in
the model demonstrated strong model performance. The
model simulated a 9.72 mL/min per 1.73 m2 average de-
crease in eGFR over 9 years. In the ARIC data, the actual
decrease in eGFR over the 9-year study period was
9.24 mL/min per 1.73 m2. The difference between the
simulated and actual change in eGFR was statistically
not different (i.e., p > 0.05).
Sensitivity analysis
To test the sensitivity of our results and conclusions to
the choice of parameters for risks and costs, we conducted
a number of one-way sensitivity analyses by varying key
model parameters by ±25%: the hazard ratio of ACE in-
hibitor/ARB treatment on transition from moderate to se-
vere albuminuria, the hazard ratio of ACE inhibitor/ARB
treatment on eGFR decline, the hazard ratio of ACE
inhibitor/ARB treatment on the annual mortality rate,
ACE inhibitor inhibitor/ARB adherence, the costs of
screening, and the costs of ACE inhibitor/ARB treat-
ment. We performed these tests for the optimal screening
scenarios for each risk score identified in the main ana-
lysis. For each test, we examined the ICER relative to the
no screening scenario and determined the percentage
change from results in the main analysis. These parame-
ters relate to the benefits and costs of early screening, so
varying them tests the sensitivity of results to these bene-
fits and costs. We also conducted probabilistic sensitivity
analysis to generate 95% confidence intervals for simula-
tion results.
Results
Table 4 shows the cost-effectiveness of screening using
the Bang et al. [15] and Kshirsagar et al. [16] risk scores
for various risk score thresholds and screening follow-up
frequencies. Using the Bang et al. risk score, lifetime
QALYs and costs had only small differences across screen-
ing scenarios, but ICERs across the screening scenarios
ranged from $8,823 per QALY to $124,626 per QALY.
With annual follow-up screening, risk score thresholds of
0.10 or higher had ICERs below the willingness to pay
benchmark of $50,000 per QALY. For both the 2-year and
5-year screening follow-up all risk score thresholds evalu-
ated had ICERs less than the willingness to pay bench-
mark. Lower risk score thresholds had higher QALYs and
in most cases also had higher ICERs than the next higher
threshold. Among the cost-effective screening scenarios, a
risk score threshold of 0.02 with 2-year follow-up had the
highest lifetime QALYs (21.373) with an ICER of $19,116
per QALY.
Using the Kshirsagar et al. risk score (Table 4), lifetime
QALYs and costs had only small differences across screen-
ing scenarios, but ICERs across the screening scenarios
ranged from $5,750 per QALY to $368,000 per QALY.
With annual follow-up screening, risk score thresholds of
0.20 and 0.15 had ICERs lower than the willingness to pay
benchmark. With 2-year follow-up, risk score thresholds
0.05 and higher had ICERs below the willingness to pay
benchmark. With 5-year follow-up, all thresholds had
ICERs lower than the willingness to pay benchmark. As
with the Bang et al. risk score, using lower risk score
thresholds had higher QALYs, however the pattern for
ICERs was inconsistent. Among the cost-effective screen-
ing scenarios, a risk score threshold of 0.05 with 2-year
follow-up screening had the highest lifetime QALYs
(21.373) with an ICER of $12,667 per QALY. Comparing
the optimal screening scenarios for the two risk scores,
both yielded the same level of QALYs, but the optimal
screening scenario using the Bang et al. score had a lower
lifetime cost and therefore can be considered optimal
overall.
Figure 2 shows the results of one-way sensitivity
analysis for 25% changes in parameter estimates on
the ICER relative to the no screening scenario when
using a risk threshold of 0.02 for the Bang et al. risk
score with 2-year follow-up screening. Varying the
costs of angiotensin-converting enzyme (ACE) inhibi-
tors/angiotensin receptor blockers (ARBs) treatment
Yarnoff et al. BMC Nephrology  (2017) 18:85 Page 6 of 11
Table 4 Cost-Effectiveness of Using the Bang et al. and Kshirsagar et al. Risk Scores to Identify Persons for CKD Screening
Screening Scenario Means ICER (2016 US $
per QALY)Lifetime Costs (2016 US $) Lifetime QALYs
No screening $139,200 21.349 —
Bang et al. risk score
1-year follow-up screening
Risk threshold = 0.20 $139,945 (134,865, 147,248) 21.366 (20.659, 21.915) $43,791 per QALY
Risk threshold = 0.15 $140,024 (135,020, 147,634) 21.367 (20.660, 21.903) $79,408 per QALY
Risk threshold = 0.10 $140,152 (135,122, 147,313) 21.370 (20.660, 21.931) $42,645 per QALY
Risk threshold = 0.05 $140,317 (134,909, 147,273) 21.372 (20.664, 21.919) $82,165 per QALY
Risk threshold = 0.02 $140,566 (133,133, 145,052) 21.374 (20.602, 21.826) $124,626 per QALY
2-year follow-up screening
Risk threshold = 0.20 $139,783 (135,227, 147,465) 21.363 (20.688, 21.912) $41,594 per QALY
Risk threshold = 0.15 $139,820 (135,201, 147,212) 21.365 (20.664, 21.888) $18,749 per QALY
Risk threshold = 0.10 $139,880 (135,064, 147,565) 21.368 (20.652, 21.938) $19,852 per QALY
Risk threshold = 0.05 $139,939 (134,902, 147,208) 21.370 (20.655, 21.904) $29,778 per QALY
Risk threshold = 0.02 $139,997 (135,199, 147,283) 21.373 (20.666, 21.923) $19,116 per QALY
5-year follow-up screening
Risk threshold = 0.20 $139,708 (135,002, 147,573) 21.361 (20.686, 21.898) $42,277 per QALY
Risk threshold = 0.15 $139,749 (135,108, 147,277) 21.363 (20.666, 21.890) $20,403 per QALY
Risk threshold = 0.10 $139,775 (135,303, 147,168) 21.366 (20.649, 21.925) $8,823 per QALY
Risk threshold = 0.05 $139,820 (134,826, 147,093) 21.368 (20.647, 21.917) $22,609 per QALY
Risk threshold = 0.02 $139,852 (134,968, 147,288) 21.371 (20.644, 21.924) $10,662 per QALY
Kshirsagar et al. risk score
1-year follow-up screening
Risk threshold = 0.20 $140,073 (135,007, 147,383) 21.366 (20.682, 21.915) $51,316 per QALY
Risk threshold = 0.15 $140,179 (135,241, 147,683) 21.369 (20.664, 21.901) $35,292 per QALY
Risk threshold = 0.10 $140,432 (135,483, 147,257) 21.371 (20.684, 21.916) $126,832 per QALY
Risk threshold = 0.05 $140,657 (135,057, 147,402) 21.374 (20.648, 21.939) $74,996 per QALY
Risk threshold = 0.02 $141,063 (135,111, 147,469) 21.375 (20.660, 21.946) $405,861 per QALY
2-year follow-up screening
Risk threshold = 0.20 $139,807 (134,840, 147,579) 21.363 (20.634, 21.916) $43,328 per QALY
Risk threshold = 0.15 $139,848 (135,096, 147,115) 21.367 (20.658, 21.929) $10,202 per QALY
Risk threshold = 0.10 $139,980 (135,162, 147,227) 21.370 (20.657, 21.899) $44,115 per QALY
Risk threshold = 0.05 $140,022 (135,378, 147,369) 21.373 (20.708, 21.909) $13,970 per QALY
Risk threshold = 0.02 $140,131 (134,999, 147,385) 21.374 (20.689, 21.918) $109,186 per QALY
5-year follow-up screening
Risk threshold = 0.20 $139,705 (135,092, 147,340) 21.361 (20.670, 21.893) $42,001 per QALY
Risk threshold = 0.15 $139,744 (135,192, 147,309) 21.365 (20.659, 21.917) $9,926 per QALY
Risk threshold = 0.10 $139,828 (135,188, 147,368) 21.367 (20.704, 21.887) $41,910 per QALY
Risk threshold = 0.05 $139,853 (134,908, 147,298) 21.371 (20.651, 21.947) $6,342 per QALY
Risk threshold = 0.02 $139,879 (134,675, 147,422) 21.372 (20.653, 21.925) $25,366 per QALY
CKD chronic kidney disease, ICER incremental cost-effectiveness ratio, QALYs quality adjusted life years. Notes: 95% confidence intervals are in parentheses. Costs
have been rounded to the nearest dollar, and QALYS have been rounded to the nearest thousandth. The Bang et al. risk score is derived from a logistic regression
to predict current CKD (stage 3+) in the NHANES population. The Kshirsagar et al. risk score is derived from a logistic regression to predict onset of CKD (stage 3+)
over the 9-year study period in subsamples of ARIC and the Cardiovascular Health Study (CHS). Coefficients used to generate the risk scores are given in Table 3
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had a large impact on the ICER relative to the no
screening scenario. Increasing treatment cost parame-
ters by 25% led to an ICER of $1,066,741 per QALY
and decreasing treatment cost parameters by 25% re-
sulted in cost savings. If costs are higher than the pa-
rameters used here, results will be very different.
Figure 3 shows a similar sensitivity analysis for the
Kshirsagar et al. risk score using a risk threshold of 0.05
and 2-year follow-up screening. Similar to the Bang et al.
risk score, only varying the costs of ACE/ARB treatment
has a large impact on the ICER relative to the no screen-
ing scenario. Increasing treatment cost parameters by 25%
led to an ICER of $1,045,704 per QALY and decreasing
treatment cost parameters by 25% resulted in cost savings.
If costs are higher than the parameters used here, results
will be very different.
Fig. 2 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.02 for the Bang et al. risk
score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers;
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate
Fig. 3 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.05 for the Kshirsagar et al.
risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers;
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate
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Discussion
The Bang et al. and Kshirsagar et al. risk scores exam-
ined here, in general, produced a similar pattern of re-
sults. Using lower risk score thresholds when identifying
persons for screening led to screening more people,
identifying more early cases of moderate albuminuria,
and saving more QALYs. However, because of costs as-
sociated with screening more persons, the incremental
costs were greater for scenarios with lower risk score
thresholds. Less frequent follow-up screening for person
above the risk score threshold whose test was negative
mitigated some of these additional costs while preserv-
ing most of the QALY gains from early detection. The
ICER here summarizes the trade-off between increased
QALYs and increased costs from broader screening. Im-
portantly in these results, for 1-year follow-up screening,
ICERs generally increased as risk thresholds decreased,
whereas for 2-year and 5-year follow-up, ICERs de-
creased as risk thresholds decreased. This result illus-
trates that, with less frequent follow-up, few of the
health gains of screening were lost while cost reductions
were substantial.
The pattern of change in ICERs when moving to each
lower risk score threshold was not always consistent due
to different rates of change in the QALYs and costs at
each threshold. Although costs and QALYs increased for
all lower risk score thresholds, they did not always in-
crease at the same rate. There were some specific differ-
ences in results between the two risk scores. The
scenarios using the Kshirsagar et al. risk score to identify
persons for screening produced slightly greater QALYs,
but generally at higher costs than scenarios using the
Bang et al. risk score at all thresholds. This could be be-
cause for each risk score threshold, the Kshirsagar et al.
risk scores classifies more persons as high risk. This
would lead to more persons screened and more QALYs
gained, albeit at greater cost.
This study showed that there were several screening
scenarios that were cost-effective for the given willing-
ness to pay benchmark. Among all the cost-effective
screening scenarios, the Kshirsagar et al. risk score with
a threshold of 0.05 and 2-year follow-up screening and
the Bang et al. risk score with threshold of 0.02 with
2-year follow-up screening generated the same max-
imum level of lifetime QALYs (21.373), but the one using
the Bang et al. risk score had lower lifetime costs than that
using Kshirsagar et al. risk score ($139,997 vs. $140,022)
and can therefore be considered optimal. However, it
should be noted that the difference in cost between these
two screening scenarios is small ($25), so a clinician could
optimally use either depending on the availability of pa-
tient data available to construct the alternative risk scores.
It should also be noted that lifetime QALYs and costs had
only small differences across all screening scenarios using
both risk scores, so little costs or QALYs are gained incre-
mentally, which should encourage caution when choosing
a particular risk score threshold especially because the
confidence intervals around lifetime costs and QALYs are
relatively large.
For clinicians, this means, each patient could be evalu-
ated using the Bang et al. risk score and screened for mod-
erate albuminuria if the risk score is greater than 0.02. For
example, persons older than age 50; those of any age with
diabetes, hypertension, and anemia; or those of any age
with a history of CVD would be candidates for CKD
screening (Table 2). If the screening test is positive, the
clinician would proceed with treatment; if negative, the
clinician would conduct a follow-up screening in 2 years.
Past studies have found that screening the broad
population for CKD may not be cost-effective, but
screening populations at high risk, such as persons with
diabetes or hypertension, may be cost-effective [12–14].
This study builds upon this past work by using risk
scores to identify persons in the broader population to
receive CKD screening. These risk scores rely not only
on diabetes and hypertension, but also on age, gender,
and health history, including CVD and anemia. Table 2
illustrates how this method of screening with risk scores
leads to screening higher risk persons based on combi-
nations of age, gender, CVD history, and anemia. These
are persons that would not have been screened based on
previous research showing that only screening those
with diabetes or hypertension is cost-effective [12–14].
Using CKD risk scores allows for the examination of
various thresholds for screening, which dichotomous cri-
teria, such as history of diabetes or hypertension, does
not. The information from this study could be used to
frame future recommendations and programs for CKD
screening that are not only effective from a clinical but
also from a cost perspective.
This analysis is limited by the need to make assump-
tions regarding costs and other model parameters such
as that all patients will present for initial and follow-up
screening and be offered and accept treatment and that
all providers will use risk scores and follow screening
guidelines. The analysis only included medical costs and
potentially omitted important societal costs, such as op-
portunity costs of time for screening, which would raise
the ICERs associated with screening, and productivity
losses and long-term care costs, which would decrease
the ICERs. In addition, although model parameters were
based on current epidemiologic literature, they may be
imperfect or may omit additional unknown factors.
Conclusions
In summary, the Bang et al. CKD risk score with a
threshold of 0.02 and 2-year follow-up was found to be
the most cost-effective for CKD screening. In contrast
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with current approaches for CKD screening that rely only
on identifying high risk persons with diabetes or hyperten-
sion, CKD risk scores could be used by clinicians to iden-
tify a broader population for CKD screening. This is an
important tool for increasing awareness of CKD and CKD
screening in patients and clinicians. In particular, people
with CKD who are detected in earlier stages of the disease
would consequently benefit from receiving earlier clinical
management and treatment to potentially slow down
progression and prevent or delay ESRD.
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